<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780854</url>
  </required_header>
  <id_info>
    <org_study_id>S-5-2020</org_study_id>
    <nct_id>NCT04780854</nct_id>
  </id_info>
  <brief_title>Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)</brief_title>
  <official_title>Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German University in Cairo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy cause many adverse events including induction of peripheral neuropathy.&#xD;
      Metformin, the AMPK activator, was found to have protective effect against chemotherapy&#xD;
      induced peripheral neuropathy in mouse model and in clinical trials as well. There are&#xD;
      different hypothesized mechanisms through which metformin does the protective effect. Such as&#xD;
      enhancing mitochondrial activity, reduction of ROS and nitric oxide and activation of AMPK.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy can cause a variety of side effects. One of the most common side effects is&#xD;
      Chemotherapy induced peripheral neuropathy (CIPN), it commonly caused by Paclitaxel&#xD;
      chemotherapy which is usually used in the treatment of breast cancer. Metformin which is&#xD;
      known as a safe anti-diabetic drug, was found to have a protective effect on neurons. It gave&#xD;
      positive results in chemotherapy induced peripheral neuropathy in mouse models and in some&#xD;
      clinical trials&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of grade 2-4 neurotoxicity in both arms</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by NCI-CTCAE system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in biological markers in both arms.</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of Nerve growth factor (NGF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in biological markers in both arms.</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of Malondialdehyde (MDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Qulaity of Life (QOL) deterioration in both arms</measure>
    <time_frame>3 months</time_frame>
    <description>Measured using Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX) questionnaire. The higher the score, the better the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of other treatment related common adverse events in both arms.</measure>
    <time_frame>3 months</time_frame>
    <description>Graded using NCI-CTCAE system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gm metformin tablet administered twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin-free</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet administered twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration</description>
    <arm_group_label>Metformin group</arm_group_label>
    <other_name>N,N-dimethylbiguanide</other_name>
    <other_name>Cidophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in the placebo group will be administered metformin free tablet as placebo twice daily</description>
    <arm_group_label>Metformin-free</arm_group_label>
    <other_name>inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age (18-75) male and female patients&#xD;
&#xD;
          -  Scheduled to be treated with single agent Paclitaxel&#xD;
&#xD;
          -  Performance status according to Eastern Cooperative oncology group (ECOG) &lt; 2.&#xD;
&#xD;
          -  Patients who are willing and able to review and provide written consent, patients who&#xD;
             can read the questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to chemotherapy drugs that cause neuropathy, patients treated with&#xD;
             medications that increase the risk of neuropathy like amiodarone, Colchicine,&#xD;
             metronidazole, phenytoin.&#xD;
&#xD;
          -  Patients with impaired liver functions or kidney functions.&#xD;
&#xD;
          -  Patients with a history of any serious adverse events or interaction or&#xD;
             hypersensitivity to Metformin.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Patients who are using metformin for any other cause.&#xD;
&#xD;
          -  Patients with sensory or motor neuropathy of any grade prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed H. Solayman, PhD. Pharm.</last_name>
    <role>Study Chair</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loay M. Kassem, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danira Ashraf Habashy, PhD Pharm.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara A. Mosa, Bsc</last_name>
    <role>Principal Investigator</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara A. Mosa, Bsc</last_name>
    <phone>+201008662223</phone>
    <email>sara.araby96@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loay Kassem</last_name>
    </contact>
    <investigator>
      <last_name>Loay Kassem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.frontiersin.org/articles/10.3389/fnmol.2017.00174/full</url>
    <description>Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.</description>
  </link>
  <link>
    <url>https://resoncol.journals.ekb.eg/article_8341_1085.html</url>
    <description>Impact of Exogenous Neurotropic Factor Administration on Occurrence and Severity of Paclitaxel-Induce Neuropathy in Breast Cancer Patients. An open label Pilot Study</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0885392417303536?via=ihub.</url>
    <description>Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study.</description>
  </link>
  <reference>
    <citation>Gaballah A, Shafik A, Elhusseiny K, Ashraf M. Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis. Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2223-2227.</citation>
    <PMID>30139229</PMID>
  </reference>
  <reference>
    <citation>Mao-Ying QL, Kavelaars A, Krukowski K, Huo XJ, Zhou W, Price TJ, Cleeland C, Heijnen CJ. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS One. 2014 Jun 23;9(6):e100701. doi: 10.1371/journal.pone.0100701. eCollection 2014.</citation>
    <PMID>24955774</PMID>
  </reference>
  <results_reference>
    <citation>Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Epub 2014 Apr 14. Review.</citation>
    <PMID>24733808</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Sara Araby Ramadan Aly Mosa</investigator_full_name>
    <investigator_title>Bsc.</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>chemotherapy-induced peripheral neuropathy</keyword>
  <keyword>metformin</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

